Moderna-backed Metagenomi sees stock fall 31% after $94M IPO (NASDAQ:MGX)

Home » Moderna-backed Metagenomi sees stock fall 31% after $94M IPO (NASDAQ:MGX)
Initial public offering hologram, night panoramic city view of Bangkok. The financial center for multinational corporations in Asia. The concept of boosting the growth by IPO process. Double exposure.

Moderna-backed Metagenomi sees stock fall 31% after $94M IPO (NASDAQ:MGX)


2d illustrations and photos/iStock via Getty Images

Moderna-backed Metagenomi Technologies (NASDAQ:MGX) stock was down 31% Friday afternoon in the wake of a $94M initial public offering that priced at the low-end of its previously stated range.

Shares of the genetic drug developer opened at $10.25 after being priced


Original article

Click here to view the original article

Share:

Share on facebook
Facebook
Share on twitter
Twitter
Share on pinterest
Pinterest
Share on linkedin
LinkedIn
On Key

Related Posts